Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share
-
Shares outstanding
-
266,212,950
-
Total 13F shares
-
379,227
-
Share change
-
+184,227
-
Total reported value
-
$2,479,272
-
Price per share
-
$6.44
-
Number of holders
-
3
-
Value change
-
+$1,186,422
-
Number of buys
-
2
Institutional Holders of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) as of Q4 2023
As of 31 Dec 2023,
Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) was held by
3 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
379,227 shares.
The largest 10 holders included
Syncona Portfolio Ltd, Blackstone Inc., Paradigm Biocapital Advisors LP, Deep Track Capital, LP, TFG Asset Management GP Ltd, Cormorant Asset Management, LP, ARMISTICE CAPITAL, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Frazier Life Sciences Management, L.P., and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
97
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.